HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of anti-angiogenesis in non-small-cell lung cancer: an update.

Abstract
Recognition of the vascular endothelial growth factor (VEGF) pathway as a key mediator of angiogenesis has led to the clinical study of several VEGF and VEGF receptor (VEGFR) targeted therapies in non-small-cell lung cancer (NSCLC). These targeted therapies include neutralizing antibodies to VEGF (bevacizumab and aflibercept) and VEGFR-2 (ramucirumab) and tyrosine kinase inhibitors (TKIs) with selectivity for the VEGFRs. Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. The VEGFR-2 TKIs have been associated with responses and improved progression-free survival in selected NSCLC settings; however, this level of activity has thus far been insufficient to confer significant survival advantages. This review will focus on the current state of VEGF targeted therapies in NSCLC.
AuthorsLiza C Villaruz, Mark A Socinski
JournalCurrent oncology reports (Curr Oncol Rep) Vol. 17 Issue 6 Pg. 26 (Jun 2015) ISSN: 1534-6269 [Electronic] United States
PMID25947099 (Publication Type: Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Bevacizumab
  • ramucirumab
  • Receptors, Vascular Endothelial Growth Factor
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents (therapeutic use)
  • Bevacizumab (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (blood supply, drug therapy)
  • Disease-Free Survival
  • Humans
  • Lung Neoplasms (blood supply, drug therapy)
  • Molecular Targeted Therapy (methods)
  • Neovascularization, Pathologic (drug therapy)
  • Protein Kinase Inhibitors (therapeutic use)
  • Receptors, Vascular Endothelial Growth Factor (therapeutic use)
  • Recombinant Fusion Proteins (therapeutic use)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: